A randomized clinical trial in Australia investigated the efficacy of cannabidiol (CBD) for severe behavioral problems in children with intellectual disabilities. The study, conducted between May 2021 and May 2025 across three Australian hospitals, involved 132 participants aged 6 to 18 with an IQ of less than 70 and deficits in adaptive functioning. Participants were randomly assigned to receive either 10 mg/kg/d CBD isolate in oil or a placebo, both taken orally for 8 weeks with a 4-week follow-up. The primary outcome measured parent-reported scores on the Aberrant Behavior Checklist, Irritability (ABC-I).
Key Clinical Findings
During the 8-week treatment period, ABC-I scores decreased from 32.2 to 21.7 in the CBD group and from 30.0 to 19.2 in the placebo group, resulting in a mean difference of 2.4 (95% CI −1.5 to 6.3). Rates of adverse events were similar between the two groups. Eighty-seven percent of patients were taking a concomitant psychotropic medication at baseline. The study included 84% participants with autism spectrum disorder.
Trial Context and Limitations
There was no advantage for CBD over placebo in any subgroup analysis. The results suggest that CBD should not be used to treat severe behavioral problems in this population. An accompanying editorial noted similarities with a North American multicenter trial and two other trials showing no behavioral benefit for CBD in youths with ASD across a broad range of cognitive abilities. The editorial highlighted the magnitude of the placebo response, emphasizing caution when interpreting apparent benefits of novel treatments. Ongoing research is evaluating CBD combined with other parts of the cannabis plant such as terpenes and small amounts of tetrahydrocannabinol.